secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095054
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Q2 net loss $21.2M; positive interim gene therapy data in FA cardiomyopathy
--------------------------------------------------------------------------------

- Net loss of $21.2M ($0.64 per share) vs $13.4M ($8.30) year ago; R&D $16.6M, G&A $7.0M.
- Cash $175M expected to fund operations into 2027.
- LX2006 for FA cardiomyopathy showed no treatment-related serious adverse events; FDA engagement for registrational study surrogate endpoints initiated.
- Phase 1/2 trial for LX2020 (PKP2-ACM) recruiting; Cohort 1 data update on track for 2H 2024.
- Tim Van Hauwermeiren (co-founder/CEO argenx) appointed to Board in July 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024095054/0000950170-24-095054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017024095054/lxeo-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer